BCX-1898
BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC50s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 345267-14-3
- 分子式: C17H32N4O3
- 分子量:340.46
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体内実験
BCX-1898 (0.01, 0.1 mg/kg/day; intranasal treatment; 20 days) demonstrates complete protection (10 out of 10 survived)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus[2]
-
Dosage:1, 10 mg/kg/day
-
Administration:Oral; 22 days
-
Result:Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus.
化学情報
-
CAS 番号 345267-14-3
-
分子量 340.46
-
分子式 C17H32N4O3
-
SMILES
CCCC(CCC)[C@@H]([C@]1([H])[C@@H](C[C@@H](C1)C(O)=O)NC(N)=N)NC(C)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. D F Smee, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001 Mar;45(3):743-8. [Content Brief]
[2]. Pooran Chand, et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem. 2005 Jun 2;13(12):4071-7. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
BCX-1898 関連分類
HY-105395 関連分類
Powered by Bioz